MADRIGAL PHARMACEUTICALS, INC. Cash and Restricted Cash
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Cash and Restricted Cash of $292.88 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $292.88M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $232.19M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $203.78M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $300.69M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $292.88M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $232.19M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $203.78M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $300.69M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $191.19M 10-Q · filed 2026-07-30 |
| 2025-03-31 | $188.65M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $105.02M 10-Q · filed 2026-07-30 |
| 2024-09-30 | $237.68M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $499.60M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $622.52M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $99.92M 10-K · filed 2026-02-19 |
| 2023-09-30 | $62.05M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $77.20M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $113.31M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $331.55M 10-K · filed 2026-02-19 |
| 2022-09-30 | $59.34M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $53.27M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $42.28M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $36.27M 10-K · filed 2025-02-26 |
| 2021-09-30 | $49.17M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $33.54M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $44.20M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $54.00M 10-K · filed 2024-02-28 |
| 2020-09-30 | $109.12M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $61.87M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $66.65M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $46.70M 10-K/A · filed 2023-03-03 |
| 2019-09-30 | $89.49M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $72.51M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $47.49M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $57.38M 10-K · filed 2022-02-24 |
| 2018-09-30 | $38.05M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $264.86M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $38.13M 10-Q · filed 2019-05-08 |
| 2017-12-31 | $148.63M 10-K · filed 2021-02-25 |
| 2017-09-30 | $12.96M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $34.80M 10-Q · filed 2018-08-07 |
| 2016-12-31 | $19.14M 10-K · filed 2020-02-26 |
| 2015-12-31 | $306.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |